Immunobiology of Facial Nerve Repair and Regeneration

Shiming, Quan; Gao, Zhiqiang

doi:10.1016/s1672-2930(06)50023-6

Cited by 7 publications

(2 citation statements)

References 63 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The NF-κβ pathway and improved CD4 + and CD8 + T-cells regulation due to decreased T-cells death were suspected to be responsible for these effects [23,26]. TQ has also been reported for its ability to enhance T-cell proliferation in experimental mice [27].…”

Section: Discussionmentioning

confidence: 99%

Thymoquinone Modifies CD4+:CD8+ Ratio without Affecting Tumor Necrosis Factor-α and Interleukin-1β Levels in Wallerian Degeneration Crush Injury Rat Model

Besin,

Bajamal,

Nugraha

et al. 2023

Preprint

View full text Add to dashboard Cite

Background Wallerian degeneration following nerve injury not only suppresses CD4 + T-cell responses but also promotes pro-inflammatory immunological responses through TNF-α and IL-1β. Recent research suggests that thymoquinone might enhance nerve recovery by exerting anti-inflammatory effects on both the innate and adaptive immune systems. This study aims to evaluate the effect of thymoquinone on neuroinflammation in a sciatic nerve crush injury, as represented by TNF-α, IL-1β, and the CD4+:CD8 + ratio.Methods In this study, 126 Wistar rats were divided into three main groups: placebo, thymoquinone 100 mg/kg, and thymoquinone 250 mg/kg administered daily. Rats were euthanised at six distinct time points: 12, 18, and 24 hours, as well as on day-5, day-6, and day-7. TNF-α and IL-1β levels were assessed using the Enzyme-Linked Immunosorbent Assay (ELISA). The CD4+:CD8 + ratio in peripheral blood was determined via flow cytometry. Data analysis was conducted using MANOVA, Kruskal-Wallis, and Mann-Whitney U tests.Results No significant difference was noted in TNF-α levels between the treatment and placebo groups across all observation times. However, on day-6, the IL-1β level in the TQ 250mg/kg group was statistically lower than in the placebo group (p = 0.008). Furthermore, both the TQ 100mg/kg and 250mg/kg groups exhibited a higher CD4+:CD8 + ratio compared to the placebo group on day-5 (p = 0.007).Conclusion Daily TQ administration did not consistently reduce TNF-α and IL-1ß levels. However, both doses elevated the CD4+:CD8 + ratio during the early stages of Wallerian degeneration, suggesting a potential benefit of TQ on nerve regeneration.

show abstract

Section: Discussionmentioning

confidence: 99%

Thymoquinone Modifies CD4+:CD8+ Ratio without Affecting Tumor Necrosis Factor-α and Interleukin-1β Levels in Wallerian Degeneration Crush Injury Rat Model

Besin,

Bajamal,

Nugraha

et al. 2023

Preprint

View full text Add to dashboard Cite

show abstract

“…It should be mentioned that PSELT is able to cross the plasma membrane in vitro and in vivo and to target different pathways in neuronal cells (Alsharif et al, 2021). Many studies pointed out the crucial role of the immune system in the process of neurodegeneration/regeneration after PNI (Gaudet et al, 2011; Greathouse et al, 2016; Quan & Gao, 2006). In the present study, PSELT was administered into the injury site, and therefore we can assume that the protective action of the peptide applies to all cells present in the injury site, including activated immune cells.…”

Section: Discussionmentioning

confidence: 99%

The SELENOT mimetic PSELT promotes nerve regeneration by increasing axonal myelination in a facial nerve injury model in female rats

Pothion

Lihrmann

Duclos

et al. 2022

J of Neuroscience Research

View full text Add to dashboard Cite

Peripheral nerve injury (PNI) is frequent and many patients suffer lifelong disabilities in severe cases. Although the peripheral nervous system is able to regenerate, its potential is limited. In this study, we tested in a nerve regeneration model in rat the potential beneficial effect of a short mimetic peptide, named PSELT, which derives from SELENOT, an essential thioredoxin‐like selenoprotein endowed with neuroprotective and antioxidant activities. For this purpose, the right facial nerve of female Long–Evans rats was axotomized then bridged with a free femoral vein interposition graft. PSELT (1 μM) was injected into the vein immediately and 48 h after the injury, and the effects observed were compared to those found after an end‐to‐end suture used as a gold standard treatment. Whisking behavior, electrophysiological potential, and histological analyses were performed 3 months after injury to determine the effects of these treatments. These analyses revealed that PSELT‐treated animals exhibit a better motor recovery in terms of protraction amplitude and velocity of vibrissae compared to control and end‐sutured nerve animal groups. Moreover, administration of PSELT following injury enhanced muscle innervation, axonal elongation, and myelination of newly formed nerve fibers. Altogether, these results indicate that a PSELT‐based treatment is sufficient to enhance facial nerve myelination and regeneration and could represent a new therapeutic tool to treat PNI.

show abstract

Thymoquinone modifies CD4+:CD8+ ratio without affecting tumor necrosis factor-α and interleukin-1β levels in Wallerian degeneration crush injury rat model

Besin,

Bajamal,

Nugraha

et al. 2024

Neurosci Behav Physi

View full text Add to dashboard Cite

Immunobiology of Facial Nerve Repair and Regeneration

Cited by 7 publications

References 63 publications

Thymoquinone Modifies CD4+:CD8+ Ratio without Affecting Tumor Necrosis Factor-α and Interleukin-1β Levels in Wallerian Degeneration Crush Injury Rat Model

Thymoquinone Modifies CD4+:CD8+ Ratio without Affecting Tumor Necrosis Factor-α and Interleukin-1β Levels in Wallerian Degeneration Crush Injury Rat Model

The SELENOT mimetic PSELT promotes nerve regeneration by increasing axonal myelination in a facial nerve injury model in female rats

Thymoquinone modifies CD4+:CD8+ ratio without affecting tumor necrosis factor-α and interleukin-1β levels in Wallerian degeneration crush injury rat model

Contact Info

Product

Resources

About